M&T Bank Corp Has $5.47 Million Stock Holdings in Edwards Lifesciences Co. (NYSE:EW)

M&T Bank Corp cut its holdings in Edwards Lifesciences Co. (NYSE:EW) by 28.9% in the 4th quarter, Holdings Channel.com reports. The firm owned 71,727 shares of the medical research company’s stock after selling 29,194 shares during the quarter. M&T Bank Corp’s holdings in Edwards Lifesciences were worth $5,470,000 as of its most recent SEC filing.

Other institutional investors and hedge funds have also modified their holdings of the company. Cambridge Investment Research Advisors Inc. lifted its stake in Edwards Lifesciences by 2.6% in the 3rd quarter. Cambridge Investment Research Advisors Inc. now owns 39,392 shares of the medical research company’s stock valued at $2,729,000 after acquiring an additional 1,011 shares in the last quarter. Verdence Capital Advisors LLC raised its stake in shares of Edwards Lifesciences by 16.3% during the 3rd quarter. Verdence Capital Advisors LLC now owns 9,321 shares of the medical research company’s stock worth $646,000 after purchasing an additional 1,303 shares in the last quarter. Mackenzie Financial Corp raised its stake in shares of Edwards Lifesciences by 13.7% during the 3rd quarter. Mackenzie Financial Corp now owns 159,116 shares of the medical research company’s stock worth $11,074,000 after purchasing an additional 19,208 shares in the last quarter. IFM Investors Pty Ltd raised its stake in shares of Edwards Lifesciences by 3.4% during the 3rd quarter. IFM Investors Pty Ltd now owns 132,773 shares of the medical research company’s stock worth $9,199,000 after purchasing an additional 4,340 shares in the last quarter. Finally, Inspire Advisors LLC bought a new stake in shares of Edwards Lifesciences during the 3rd quarter worth approximately $545,000. 79.46% of the stock is currently owned by institutional investors and hedge funds.

Wall Street Analysts Forecast Growth

EW has been the topic of a number of research analyst reports. Evercore ISI dropped their price target on Edwards Lifesciences from $92.00 to $89.00 and set an “in-line” rating on the stock in a research note on Friday, April 26th. StockNews.com upgraded Edwards Lifesciences from a “hold” rating to a “buy” rating in a research note on Monday, April 29th. Mizuho increased their price target on Edwards Lifesciences from $95.00 to $105.00 and gave the company a “buy” rating in a research note on Thursday, April 11th. Morgan Stanley upped their price objective on Edwards Lifesciences from $95.00 to $103.00 and gave the company an “overweight” rating in a report on Thursday, March 21st. Finally, Bank of America raised Edwards Lifesciences from a “neutral” rating to a “buy” rating in a report on Thursday, March 7th. One investment analyst has rated the stock with a sell rating, six have given a hold rating and eleven have given a buy rating to the company. According to data from MarketBeat, the stock has a consensus rating of “Moderate Buy” and an average target price of $92.71.

Insider Buying and Selling at Edwards Lifesciences

In other Edwards Lifesciences news, VP Daniel J. Lippis sold 1,715 shares of the firm’s stock in a transaction that occurred on Thursday, March 7th. The stock was sold at an average price of $90.98, for a total value of $156,030.70. Following the completion of the sale, the vice president now owns 17,213 shares of the company’s stock, valued at $1,566,038.74. The sale was disclosed in a legal filing with the Securities & Exchange Commission, which is available at this hyperlink. In related news, CFO Scott B. Ullem sold 7,255 shares of Edwards Lifesciences stock in a transaction on Monday, April 1st. The stock was sold at an average price of $94.89, for a total transaction of $688,426.95. Following the sale, the chief financial officer now directly owns 19,074 shares in the company, valued at $1,809,931.86. The sale was disclosed in a filing with the Securities & Exchange Commission, which is accessible through this hyperlink. Also, VP Daniel J. Lippis sold 1,715 shares of Edwards Lifesciences stock in a transaction on Thursday, March 7th. The stock was sold at an average price of $90.98, for a total value of $156,030.70. Following the sale, the vice president now owns 17,213 shares in the company, valued at $1,566,038.74. The disclosure for this sale can be found here. Over the last quarter, insiders sold 237,749 shares of company stock valued at $20,920,934. Company insiders own 1.27% of the company’s stock.

Edwards Lifesciences Price Performance

Edwards Lifesciences stock opened at $85.09 on Tuesday. The company has a current ratio of 3.75, a quick ratio of 2.67 and a debt-to-equity ratio of 0.08. The company has a market capitalization of $51.28 billion, a PE ratio of 36.68, a P/E/G ratio of 3.59 and a beta of 1.10. Edwards Lifesciences Co. has a 12 month low of $60.57 and a 12 month high of $96.12. The stock has a 50-day moving average price of $90.06 and a two-hundred day moving average price of $79.58.

Edwards Lifesciences (NYSE:EW) last issued its quarterly earnings data on Thursday, April 25th. The medical research company reported $0.66 earnings per share (EPS) for the quarter, topping analysts’ consensus estimates of $0.64 by $0.02. Edwards Lifesciences had a return on equity of 22.86% and a net margin of 23.01%. The company had revenue of $1.60 billion during the quarter, compared to the consensus estimate of $1.58 billion. Analysts expect that Edwards Lifesciences Co. will post 2.77 EPS for the current year.

Edwards Lifesciences Company Profile

Edwards Lifesciences Corporation provides products and technologies for structural heart disease and critical care monitoring in the United States, Europe, Japan, and internationally. It offers transcatheter heart valve replacement products for the minimally invasive replacement of aortic heart valves under the Edwards SAPIEN family of valves system; and transcatheter heart valve repair and replacement products to treat mitral and tricuspid valve diseases under the PASCAL PRECISION and Cardioband names.